Semaglutide and tirzepatide are the two most talked-about weight-loss and diabetes medicines, and they are frequently cross-shopped. Both are once-weekly injectable incretin mimetics with large, completed clinical trials behind them — but they are not the same drug. Semaglutide activates a single hormone receptor (GLP-1); tirzepatide activates two (GIP and GLP-1). In head-to-head and indirect comparisons, the dual mechanism has generally translated into greater average weight loss, at the cost of a broadly similar gastrointestinal side-effect profile.
At a glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Drug class | Single GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| FDA status | Approved (T2D & chronic weight management) | Approved (T2D & chronic weight management) |
| Typical trial weight loss | ~15% of body weight (STEP program) | ~20–22% of body weight (SURMOUNT program) |
| Dosing | Once weekly injection; daily oral option (Rybelsus) | Once weekly injection |
| Main side effects | Nausea, diarrhea, constipation (GI-dominant) | Nausea, diarrhea, constipation (GI-dominant) |
| Evidence level | Large randomized trials, FDA-approved | Large randomized trials, FDA-approved |
The bottom line
Bottom line: On average, tirzepatide has produced the larger weight loss in trials, likely because it engages a second incretin pathway (GIP) alongside GLP-1. Semaglutide remains a highly effective, longer-on-market option and is the only one of the two with an oral form. Both are prescription medicines with the same GI-dominated side effects and both require medical supervision — the "better" choice is an individual clinical decision, not a universal winner.
Frequently asked questions
Is tirzepatide better than semaglutide for weight loss?
In trials, tirzepatide produced a larger average weight loss (~20–22% vs ~15%), but results are highly individual and depend on dose, diet, and tolerance. Both are effective, FDA-approved prescription medicines and the right choice should be made with a clinician.
What is the main difference between semaglutide and tirzepatide?
Semaglutide activates one incretin receptor (GLP-1), while tirzepatide is a dual agonist that activates both GIP and GLP-1 receptors. The added GIP activity is thought to contribute to tirzepatide's larger weight-loss effect.
Do semaglutide and tirzepatide have different side effects?
Both share a gastrointestinal-dominant side-effect profile — nausea, diarrhea and constipation are most common, usually easing over time. Both carry the same class warnings (including a rodent thyroid C-cell tumor signal) and need medical oversight.
Can you switch from semaglutide to tirzepatide?
Switching between incretin medicines is a clinical decision made by a prescriber, who will manage dose titration and monitoring. This page is educational only and not medical advice.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. Peer-reviewed study
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. Peer-reviewed study
- Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023. Peer-reviewed study
- Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. Peer-reviewed study
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. Peer-reviewed study
- Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022. Peer-reviewed study
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. Peer-reviewed study
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. Peer-reviewed study
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025. Peer-reviewed study
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. Peer-reviewed study
- Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. Peer-reviewed study
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. Peer-reviewed study